The U.S. Food and Drug Administration (FDA) has approved FoundationOne CDx, Foundation Medicine’s companion diagnostic test to help identify if patients with pediatric low-grade…
News
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) as a treatment for mantle cell lymphoma (MCL), a rare and…
GYNECOLOGICAL CANCER
Findings can differ in 2 genetic tests guiding ovarian cancer treatment
Discrepancies were identified between two genetic analysis platforms used to detect mutations that guide the treatment of ovarian, fallopian tube, or primary peritoneal cancers in…
Abbvie is teaming up with China-based company Simcere Zaiming to advance the development of SIM0500, Simcere’s experimental treatment for multiple myeloma that’s…
PANCREATIC CANCER
Germany clears pelareorep pancreatic cancer trial continuation
Authorities in Germany have given Oncolytics Biotech the go-ahead to continue enrollment in a Phase 1/2 clinical trial testing the company’s viral therapy pelareorep…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to a novel brain cancer treatment — one designed for malignant gliomas…
GYNECOLOGICAL CANCER
Medicaid expansion can raise demand for gynecologic cancer care
An expansion of Medicaid services in the state of Virginia led within months to more young and middle-aged women of lower income being treated in…
A subcutaneous, or under-the-skin, formulation of Sarclisa (isatuximab) is just as effective as the approved intravenous (into-the-vein) version of the therapy at controlling treatment-resistant…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative treatment for acute myeloid leukemia…
PANCREATIC CANCER
MEK inhibitor IMM-1-104 shows promise in pancreatic cancer: Data
Investigational oral therapy IMM-1-104 was well tolerated and showed early signs of efficacy as a first- or second-line treatment for pancreatic cancer. That’s according…
Recent Posts
- Vyriad targets 2026 clinical trial for new experimental cell therapy VV169
- Olverembatinib and chemo show deep response in trial for Ph-positive ALL
- Pancreatic cancer treatment atebimetinib set for Phase 3 trial
- 1st trial participant receives Alpha DaRT radiation therapy for glioblastoma
- How my reflection has changed since becoming a caregiver
